News

TBPN Network - Earli announces another $44M in funding (total now: $104M) from former J&J CEO Alex Gorsky & his family office Alderline Group, Accentures Ventures, Han River Partners (S Korea), along with prior investors a16z, Khosla, Perceptive Advisors.

The Scientist - Interview: Turning Tumors Against Themselves From the Inside.

White House Cancer Moonshot Fact Sheet: Earli highlighted as a key initiative for future cancer treatment technologies.

S. Korea #1 Business Newspaper Maeil: Ordering Cancer Cells to "Self-Destruct"? U.S. Biotech Firm Unveils Breakthrough Gene Technology (in Korean language/translated).

Fast Company feature story: The fundamental change Earli may bring to patients: A cancer genius died from cancer. His startup is getting revenge.

Genetic Engineering & Biotechnology News: How Earli built a world-class team to solve one of the most difficult science problems: “Synthetic” Biomarkers Light Up Hidden Malignant Cancers.

Drug Discovery Trends: Earli's newest partnership. Earli and Accenture partner in quest to turn cancer against itself.

Newsweek Opinion: Why early detection misses the mark without Early Treatment: One Glaring Problem in the U.S. Plan to Reduce Cancer Deaths.

CGT Live: Using DNA Nanoplasmids as a Diagnostic Tool in Cancer.

Tech Target: Using a synthetic targeting platform that forces cancer cells to express synthetic biomarkers, Earli Inc. is developing strategies for early cancer detection.

Entrepreneur: The Heartbreaking Loss of a Child to Cancer Brought These 3 Founders Together.

Pharmaceutical Technology: Accenture Invests in Earli's Cancer Detection Tech.

Sydney Morning Herald: Earli’s human trial: Australia’s ‘high quality’ clinical trials lure Silicon Valley cancer fighting company.

World Economic Forum selects Earli: 100 firms worldwide to join its Global Innovator community.

Fast Company: Earli the only early cancer detection firm in list of 2021 World Changing Ideas.

WIRED Feature: How Earli forces cancer to draw a “map” to itself: A Proactive Way to Detect Cancer at Its Earliest Stages.

The Atlantic: Medical Revolution Too Late for the Man Who Started It.

Nikkei: Cancer treatment: control over early detection (in Japanese language).

Tough Tech Today: Co-founder Cyriac Roeding tells the story of Earli in a video podcast.

S. Korea: Medical Newspaper: A new frontier in cancer treatment: controlling cancer cells and making them self-destruct (in Korean Language)

German BusinessWeek (Wirtschaftswoche): tells the story and breakthrough potential of Earli (in German language).

Forbes: This Company Raised $40 Million To Make Tumors Reveal Themselves.

Business Wire: Earli raises $40M in Series A funding led by Khosla Ventures, with Perceptive Advisors, Casdin Capital, Andreessen Horowitz, Sands Capital, two years after its $19.5M Seed round led by Andreessen Horowitz’s Bio Fund.

Stat News: Sam Gambhir described how new ways to detect cancer early will help pave the way for precision health.

A New Frontier in Cancer Treatment | DLD Munich 25

At DLD Munich 2025, Cyriac Roeding, captivated the audience when describing Earli's transformative approach to early cancer detection, showcasing its potential to redefine the future of healthcare.

How AI Is Powering Earli's Mission

Henry Lee, a senior biotechnician, has seen how AI powers Earli’s mission—automating cancer imaging, designing proteins, and driving breakthroughs to transform early cancer detection and treatment.

What Makes Working at Earli Unique: A New Hire’s Perspective

Experience Earli from the perspective of a new hire, where each day presents an exciting opportunity to contribute to groundbreaking innovations and be part of something truly impactful.

An Earli Halloween

A photo essay celebrating the creativity of Earli's scientists the company's annual Halloween celebration, which featured giant homemade llamas, Men in Black, and a cast of Seussian characters.

An Unconventional Path In Australia

In April 2022, Earli CEO Cyriac Roeding traveled to Australia to check-in on the progress of the first clinical trial for the synthetic biopsy nearly one year after it began.

‘Turning a Spark Into a Bonfire’: An Interview with Earli CSO David Suhy

An interview with David Suhy, the Chief Science Officer and cofounder of Earli, on synthetic biopsy, the benefits of working on medical tech in a commercial context, and more.

'Acknowledge Your Fear and Then Act Anyway’: Earli CEO Cyriac Roeding on Values and Launching A Human Trial Within 3 Years From Foundation

An interview with Cyriac Roeding, the CEO and cofounder of Earli, on how he’s applying lessons from software development to a biotech company, the future of early cancer detection, and more.

How Dogs Led the Way to Earli’s First Human Clinical Trials

For the past two years, Earli has been working with a team at UC Davis to demonstrate the safety and efficacy of Earli’s breakthrough early cancer detection technology in canine patients.

The Story of Earli

Here's Earli co-founder and CEO Cyriac Roeding in a wide-ranging interview with Tough Tech Today podcast hosts Forrest Meyen and Jonathan Miller. Cyriac discusses Earli’s origins in the laboratories

Earli the only early cancer detection firm in Fast Company’s list of World Changing Ideas

The global pandemic made the past year challenging in so many ways. But it’s important not to lose sight of the progress that was made in other areas despite the hardship.

Earli's World-Class Scientific Advisors On Early Cancer Detection

Earli’s Scientific Advisory Board consists of some the brightest minds in oncology in the world, including directors of the world’s leading cancer research institutes and Nobel laureates for the

What the Hack is a Lab-a-thon?

Take a hackathon and swap out the source code for genetic code. Add cell cultures, riboswitches, and RNA to the mix. Then give a team of gifted biologists 24 hours to develop a prototype or run an

World Economic Forum Names Earli A Global Innovator

The Covid-19 pandemic has taken over 3.4 million lives worldwide since 2020. Every single one of these deaths is a tragedy. By comparison, each year around three times as many people will die...

What It's Like to Work at Earli

When Shereen Asad joined Earli as its sixth employee in 2019, her job description didn’t exactly say anything about selling human blood samples. The possibility never even crossed her mind...

Beyond Liquid Biopsies: How the Synthetic Biopsy Leads the Next Generation of Early Cancer Detection

Despite the progress made in treatment and prevention in recent years, cancer remains the number two killer in the United States after heart disease. The high mortality rates are largely due to the...

Earlies Talk About Earli

Earli is a diverse team united by a radical vision: Make Cancer A Benign Experience. At Earli, our team is developing a new approach to early cancer detection that applies state-of-the-art...